Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) CEO William Quinn sold 9,132 shares of the company’s stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $3.24, for a total value of $29,587.68. Following the completion of the transaction, the chief executive officer directly owned 25,384 shares of the company’s stock, valued at approximately $82,244.16. This trade represents a 26.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Bolt Biotherapeutics Stock Performance
Shares of NASDAQ:BOLT traded up $0.03 during trading on Monday, hitting $3.59. 22,454 shares of the stock were exchanged, compared to its average volume of 27,365. The company has a market capitalization of $6.93 million, a price-to-earnings ratio of -0.22 and a beta of 1.09. The company has a debt-to-equity ratio of 1.47, a quick ratio of 2.61 and a current ratio of 2.61. Bolt Biotherapeutics, Inc. has a 1-year low of $3.10 and a 1-year high of $7.20. The company’s fifty day simple moving average is $3.84 and its 200-day simple moving average is $4.29.
Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($4.57) EPS for the quarter, missing the consensus estimate of ($3.39) by ($1.18). Bolt Biotherapeutics had a negative return on equity of 126.23% and a negative net margin of 611.47%.The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.50 million. Sell-side analysts expect that Bolt Biotherapeutics, Inc. will post -11.1 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
View Our Latest Analysis on BOLT
Institutional Investors Weigh In On Bolt Biotherapeutics
Hedge funds have recently made changes to their positions in the company. Nan Fung Group Holdings Ltd bought a new position in Bolt Biotherapeutics during the 2nd quarter valued at about $19,250. Renaissance Technologies LLC grew its stake in Bolt Biotherapeutics by 40.3% during the first quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock worth $312,000 after buying an additional 22,200 shares during the last quarter. Finally, T3 Companies LLC acquired a new stake in shares of Bolt Biotherapeutics during the fourth quarter worth approximately $208,000. Institutional investors and hedge funds own 86.70% of the company’s stock.
Bolt Biotherapeutics Company Profile
Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s platform is designed to stimulate the body’s innate and adaptive immune systems to recognize and attack tumor cells.
Bolt’s technology includes Boltbody™ immune-stimulating antibody conjugates, or ISACs. These therapies are intended to combine the targeting capabilities of antibodies with immune-activating components that can recruit and enhance the activity of immune cells within the tumor microenvironment.
The company’s development programs have included BDC-1001, an investigational HER2-targeted ISAC for the treatment of HER2-expressing solid tumors, and BDC-3042, an investigational antibody intended to activate macrophages through the Dectin-2 pathway.
Featured Stories
- Five stocks we like better than Bolt Biotherapeutics
- Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
- Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
- AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
- Insiders Signal Deep Value In DICK’s Sporting Goods
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
